title: Cytoreductive surgery and perioperative intraperitoneal chemotherapy in recurrent ovarian cancer.
abstract: OBJECTIVE
  Cytoreductive surgery with perioperative intraperitoneal chemotherapy is another approach for recurrent ovarian cancer. The purpose of the study was to assess the feasibility and the effect of cytoreduction and perioperative intraperitoneal chemotherapy in recurrent ovarian cancer.
  
  
  METHODS
  Twenty-nine women with recurrent ovarian cancer underwent cytoreductive surgery. Clinical variables were correlated to morbidity, hospital mortality, recurrences, and survival.
  
  
  RESULTS
  Complete cytoreduction was possible in 58.6%. Extensive seeding of the small bowel and distant metastases excluded the possibility of performing complete cytoreduction. Perioperative intraperitoneal chemotherapy was given in 75.9%. Morbidity and hospital mortality rates were subsequently 24.1% and 3.4%. Recurrence was recorded in 48.3%. The extent of peritoneal dissemination was an independent variable of recurrence (P= 0.014). The 5-year survival rate was 30%. The extent of peritoneal dissemination and the completeness of cytoreduction were related to survival (P <0.05). The completeness of cytoreduction independently influenced survival (P= 0.013).
  
  
  CONCLUSIONS
  Secondary cytoreduction with intraperitoneal chemotherapy is feasible in most women with recurrent ovarian cancer with acceptable morbidity and mortality. Complete cytoreduction is not possible if distant and unresectable metastases are present or if the small bowel is extensively seeded. Long-term survivors are patients with limited peritoneal dissemination who may undergo complete cytoreduction.
authors.affiliation: Department of Surgery, Didimotichon General Hospital, Greece. atentes@did-hosp.gr
authors.forename: Antonios-Apostolos K
authors.initials: AA
authors.lastname: Tentes
authors.forename: Odysseas S
authors.initials: OS
authors.lastname: Korakianitis
authors.forename: Stylianos
authors.initials: S
authors.lastname: Kakolyris
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Kyziridis
authors.forename: Dousan
authors.initials: D
authors.lastname: Veliovits
authors.forename: Chrysa
authors.initials: C
authors.lastname: Karagiozoglou
authors.forename: Evanthia
authors.initials: E
authors.lastname: Sgouridou
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Moustakas
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D007263:Infusions, Parenteral; D007813:Laparotomy; D008499:Medical Records; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D010534:Peritoneal Neoplasms / Q000556:secondary / Q000601:surgery*; D012189:Retrospective Studies; D016896:Treatment Outcome